Reversed-phase HPLC is the default method for reporting peptide purity, and understanding what the number does and does not cover is essential before comparing suppliers.
Key Takeaways
- A purity figure from reversed-phase HPLC is an area percentage at a detection wavelength, not a mass fraction.
- Look for whether the main peak is integrated broadly enough to swallow shoulders, and whether the baseline is stable.
- A defensible certificate of analysis states the method, column, gradient, wavelength, and batch number alongside the chromatogram.
What the percentage actually means
A purity figure from reversed-phase HPLC is an area percentage at a detection wavelength, not a mass fraction. UV-active impurities are counted, while water, salts, and non-absorbing material are not, which is why the number is systematically flattering.
Method parameters that move the result
Gradient slope, column chemistry, temperature, and detection wavelength all change the profile. A shallow gradient on a C18 column at 214 nm is the common convention, and results from different methods should not be compared directly.
For related mechanism work, see amino acid analysis peptides.
Reading a chromatogram critically
Look for whether the main peak is integrated broadly enough to swallow shoulders, and whether the baseline is stable. A single sharp peak with a clean baseline is a good sign; a purity figure quoted without the chromatogram is not.
Orthogonal confirmation
Because HPLC is not structurally specific, identity should be confirmed separately by mass spectrometry. A pure but wrong peptide is a common and expensive failure mode that purity testing alone cannot catch.
Documentation standards
A defensible certificate of analysis states the method, column, gradient, wavelength, and batch number alongside the chromatogram. A single percentage without method detail is a marketing figure rather than an analytical result.
Experimental Conditions and Practical Setup
A routine purity run uses a C18 column at 30–60 °C with a water-acetonitrile gradient containing 0.1 percent trifluoroacetic acid, detecting at 214 nm. Column temperature is controlled because retention time shifts with temperature, and a blank gradient is run before samples to confirm there is no carry-over from a previous injection.
Standard reversed-phase parameters for peptide purity
| Parameter | Typical setting | Reason |
|---|---|---|
| Detection wavelength | 214 nm | Peptide bond absorbance |
| Ion-pairing agent | 0.1% TFA in both phases | Sharpens peaks, improves retention |
| Column | C18, 3–5 µm particle | General-purpose reversed phase |
| Column temperature | 30–60 °C | Improves reproducibility of retention |
| Reported value | Area percent at set wavelength | Not a mass fraction |
Practical Notes for the Bench
- Ask for the chromatogram, not just the purity percentage.
- Confirm identity by mass spectrometry separately from purity.
- Never compare purity figures generated by different methods.
Frequently Asked Questions
Is 99% purity the same as 99% peptide by mass?
No. It is an HPLC area percentage at a set wavelength and excludes water, salts, and non-UV-active material.
Which wavelength is standard?
Peptide bonds absorb near 214 nm, which is the usual detection wavelength for purity determinations.
Can HPLC confirm the peptide is the right one?
No. Purity and identity are separate questions; mass spectrometry is needed for identity confirmation.
Why does the same peptide give different purity values at two labs?
Because gradient slope, column chemistry, temperature, and wavelength all move the result. Values are only comparable when the method is identical.
Related Reading
- amino acid analysis peptides
- peptide forced degradation
- peptide content vs purity
- peptide-drug conjugates
- dietary immunomodulatory peptides
References & Further Reading
- Ioppolo JA et al. Development of a high-performance liquid chromatography method for rapid radiochemical purity measurement of [(18) F]PSMA-1007, a PET radiopharmaceutical for detection of prostate cancer. J Labelled Comp Radiopharm. 2023. PubMed 36649714
- Strege MA et al. Enantiomeric purity analysis of synthetic peptide therapeutics by direct chiral high-performance liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2023. PubMed 36857849
- Liu W et al. [Applications of high performance liquid chromatography-mass spectrometry in proteomics]. Se Pu. 2024. PubMed 38966969
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- FDA guidance documents on peptide drug products
The notes below reflect common laboratory practice and open literature. They are not clinical recommendations, and peptides discussed are research materials unless stated otherwise.
Reviewed by Dr. Elena Marchetti, Peptide Chemistry & Analytical Characterization.